Vancomycin intermediate and resistant Staphylococcus aureus. What the nephrologist needs to know

Area of Science:

• Clinical Microbiology
• Infectious Diseases
• Nephrology

Background:

• Patients undergoing hemodialysis are at increased risk for antimicrobial resistance.
• Emerging resistance from vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant S. aureus (VRSA) poses a significant threat.
• Laboratory detection of VISA and VRSA is complex, necessitating refined diagnostic algorithms.

Purpose of the Study:

• To highlight the heightened risk of VISA and VRSA in hemodialysis patients.
• To discuss challenges in laboratory detection and effective treatment options.
• To emphasize the importance of infection control and antimicrobial stewardship.

Main Methods:

• Review of current literature on VISA and VRSA in hemodialysis settings.
• Analysis of antimicrobial susceptibility patterns for emerging strains.
• Evaluation of prevention strategies, including vancomycin use and infection control.

Main Results:

• Hemodialysis patients are particularly vulnerable to VISA and VRSA.
• Several newer and older antimicrobials show activity against VISA and VRSA strains.
• VISA and VRSA often emerge from existing methicillin-resistant S. aureus (MRSA) and vancomycin-resistant enterococci (VRE) reservoirs.

Conclusions:

• Effective laboratory detection algorithms are essential for managing VISA and VRSA.
• Appropriate vancomycin use and stringent infection control are critical for prevention.
• Containment of MRSA and VRE transmission is paramount to curb the rise of VISA and VRSA in hemodialysis patients.